Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastric/Gastroesophageal Junction Cancer Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma
Interventions
Rivoceranib, Placebo
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
Interventions
Futibatinib
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05052801
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Bemarituzumab, mFOLFOX6, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Anchorage, Alaska • Phoenix, Arizona • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions
TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (givastomig), durvalumab, chemotherapy
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Results available

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

NCT02443324
View directory record Official record
Conditions
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
Interventions
Ramucirumab, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 23, 2026, 5:03 PM EDT
Active, not recruiting Phase 1 Interventional

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

NCT04220827
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NCT01450696
View directory record Official record
Conditions
Gastric Cancer
Interventions
Capecitabine, Cisplatin, Herceptin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

NCT00780494
View directory record Official record
Conditions
Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
Interventions
bevacizumab, carboplatin, capecitabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

NCT02037048
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, radiation therapy, carboplatin, paclitaxel
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

NCT00256321
View directory record Official record
Conditions
Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Oxaliplatin, Capecitabine, Celecoxib
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

NCT00054457
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
28
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

NCT00003237
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, paclitaxel, surgical procedure
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
28
States / cities
Chicago, Illinois • Evanston, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 1Phase 2 Interventional

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

NCT04278144
View directory record Official record
Conditions
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
Interventions
BDC-1001, Nivolumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

NCT01939275
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IA Gastric Cancer, Stage IB Gastric Cancer, Stage IIA Gastric Cancer, Stage IIB Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
copper Cu 64-DOTA-trastuzumab, positron emission tomography, laboratory biomarker analysis, Computed Tomography
Radiation · Device · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional

Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

NCT00183898
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer
Interventions
oxaliplatin, capecitabine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

NCT00711243
View directory record Official record
Conditions
Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, fluorouracil, oxaliplatin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional Results available

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

NCT05980416
View directory record Official record
Conditions
Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
Interventions
EO-3021, Ramucirumab (CYRAMZA®), Dostarlimab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 23, 2026, 5:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487
View directory record Official record
Conditions
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
Interventions
NDI-101150, Pembrolizumab
Drug
Lead sponsor
Nimbus Saturn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of SC-007 in Subjects With Advanced Cancer

NCT03253185
View directory record Official record
Conditions
Colorectal Cancer (CRC), Gastric Cancer
Interventions
SC-007
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Rochester, Minnesota • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Study of SRF617 in Patients With Advanced Solid Tumors

NCT04336098
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

NCT00848783
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer
Interventions
Irinotecan, Cisplatin, Surgery, Floxuridine, Capecitabine
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

NCT00253370
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
Interventions
BAY 43-9006, docetaxel, cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Jul 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

NCT03283761
View directory record Official record
Conditions
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D, Leucovorin 400 mg/m^2
Drug
Lead sponsor
Al B. Benson, III, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Lake Forest, Illinois • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 23, 2026, 5:03 PM EDT